Every Oral GLP-1 Option in July 2026: Prices, Formats, and Where to Get Them

As of July 2026, there are exactly three FDA-approved oral GLP-1 medications on the market — and a much larger, murkier world of compounded sublingual drops, dissolvable tablets, capsules, and gummies sold through telehealth clinics. Both categories claim to solve the same problem: getting a GLP-1 receptor agonist into your body without a needle. They do it in very different ways, with very different levels of evidence behind them.

This guide lays out every option we track, what it actually costs, what format it comes in, and where the real science stops and the marketing starts.

The FDA-Approved Oral Options

Only three oral GLP-1 products have gone through FDA review. Everything else on this page is a compounded product made by a licensed pharmacy from an individual prescription — not an FDA-approved drug.

Rybelsus (oral semaglutide, approved 2019)

Rybelsus was the first oral GLP-1 to reach the market, but it's approved only for type 2 diabetes, not weight management, and weight loss is a secondary effect rather than the primary indication. It uses a permeation-enhancer technology called SNAC to help the semaglutide molecule survive the stomach and cross into the bloodstream — even so, the FDA label puts oral bioavailability at only about 0.4% to 1%. In the PIONEER 1 trial, the 14mg dose produced a modest 2.3 kg placebo-adjusted weight loss at 26 weeks, well below what injectable semaglutide or tirzepatide produce.

Wegovy Pill (oral semaglutide, approved December 22, 2025)

Novo Nordisk's oral Wegovy uses the same SNAC technology as Rybelsus but is approved specifically for chronic weight management. In the OASIS trial program, the high-dose formulation produced weight loss in the same range as the injectable pen, though Novo's own reporting (a 16.6% mean loss at 64 weeks among fully adherent patients in OASIS 4) and the treatment-policy figure in the NEJM abstract (13.6%) reflect two different ways of counting the same data — worth knowing if you see both numbers cited elsewhere.

Foundayo / orforglipron (approved April 2026)

Foundayo is Eli Lilly's entry, and it works differently from the other two: it's a small, non-peptide molecule rather than a modified peptide, so it doesn't need SNAC or any absorption enhancer at all. That's also why it's the only oral GLP-1 that can be taken any time of day, with or without food or water — no 30-minute waiting window. In the ATTAIN-1 trial, orforglipron produced roughly 11–12% weight loss at 72 weeks (sources differ slightly depending on the statistical estimand used). LillyDirect self-pay pricing runs from $149/mo at the starting 0.8mg dose up to $299–$349/mo at the higher maintenance doses, with a $25/mo price for many commercially insured patients and a $50/mo Medicare Part D price that took effect July 1, 2026.

Full Price & Format Comparison

Here's every option we track side by side. Compounded formulations are not FDA-approved and are prepared by a licensed pharmacy based on an individual prescription.

⚠️ MEDVi has received an FDA warning letter regarding marketing practices (see card below). † Wellorithm's oral/sublingual format is still being confirmed directly with the provider — treat this listing as reported, not verified.

The Compounded Oral Market: What You're Actually Buying

Compounded oral and sublingual GLP-1 products are not copies of Rybelsus, the Wegovy pill, or Foundayo. Most skip the SNAC technology entirely and instead rely on the idea that a large peptide molecule can be absorbed through the tissue under the tongue. Semaglutide is a roughly 4,000-dalton peptide, and the available evidence suggests that without a validated permeation enhancer, sublingual absorption of a molecule that size is low and inconsistent — published human clinical data on sublingual semaglutide bioavailability doesn't currently exist. That doesn't mean these products do nothing for every patient, but it does mean the pharmacological consistency is a different proposition than an FDA-approved tablet or an injectable pen.

Here's the current lineup of providers offering compounded oral or sublingual GLP-1 formats:

Format at a Glance

"Oral GLP-1" covers several genuinely different delivery formats, each with its own trade-offs. We break this down in full in our format comparison guide, but the short version:

• SNAC-enabled tablets (Rybelsus, Wegovy pill) — the only format with published human bioavailability data and FDA approval.
• Small-molecule tablets (Foundayo) — a completely different mechanism that doesn't need a permeation enhancer.
• Sublingual drops / dissolvable tablets (most compounded providers) — rely on under-the-tongue absorption; unproven at the human clinical level for a molecule this size.
• Gummies (Eden) — a swallowed, compounded format positioned mainly for convenience and taste rather than a specific absorption technology.

Which Option Actually Makes Sense

• Want the strongest evidence behind the pill you're taking? Foundayo or the Wegovy pill are your only FDA-approved weight-management options — see our head-to-head comparison.
• Priced out of the brand-name pill and want the lowest-cost oral route? See our full oral semaglutide price comparison.
• Specifically looking for oral tirzepatide? Read our oral tirzepatide guide first — the science here is less settled than for semaglutide.

Bottom Line

The oral GLP-1 category split into two very different markets in 2026: a small, well-studied FDA-approved tier (Rybelsus, Wegovy pill, Foundayo) and a much larger compounded tier built on sublingual and dissolvable formats with far less clinical evidence behind them. Both can be reasonable options depending on your budget, insurance situation, and tolerance for unproven technology — just make sure you know which tier you're buying into before you check out.